These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33433804)

  • 21. Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies.
    Chambers JD; Pope EF; Wilkinson CL; Neumann PJ
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1240-1246. PubMed ID: 30479201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the Affordable Care Act's young adult insurance expansion on prescription drug insurance coverage, utilization, and expenditures.
    Look KA; Arora P
    Res Social Adm Pharm; 2016; 12(5):682-98. PubMed ID: 26632980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.
    Brouwer ED; Basu A; Yeung K
    Pharmacoeconomics; 2019 Oct; 37(10):1287-1300. PubMed ID: 31270747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Predictive Model to Estimate Cost Savings of a Novel Diagnostic Blood Panel for Diagnosis of Diarrhea-predominant Irritable Bowel Syndrome.
    Pimentel M; Purdy C; Magar R; Rezaie A
    Clin Ther; 2016 Jul; 38(7):1638-1652.e9. PubMed ID: 27261204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
    Yeung K; Dusetzina SB; Basu A
    JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surprising ways to cut your drug costs: even with insurance you might be paying too much.
    Consum Rep; 2013 Sep; 78(9):26-30. PubMed ID: 23930299
    [No Abstract]   [Full Text] [Related]  

  • 27. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.
    Tack J; Stanghellini V; Mearin F; Yiannakou Y; Layer P; Coffin B; Simren M; Mackinnon J; Wiseman G; Marciniak A;
    BMC Gastroenterol; 2019 May; 19(1):69. PubMed ID: 31064345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utilization and Costs of Compounded Medications for Commercially Insured Patients, 2012-2013.
    McPherson T; Fontane P; Iyengar R; Henderson R
    J Manag Care Spec Pharm; 2016 Feb; 22(2):172-81. PubMed ID: 27015256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards.
    Bendicksen L; Rome BN; Avorn J; Kesselheim AS
    Milbank Q; 2021 Dec; 99(4):1162-1197. PubMed ID: 34375015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of formulary drug exclusion policies on patients and healthcare costs.
    Chambers JD; Rane PB; Neumann PJ
    Am J Manag Care; 2016 Aug; 22(8):524-31. PubMed ID: 27541699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis.
    Riemsma R; Al M; Corro Ramos I; Deshpande SN; Armstrong N; Lee YC; Ryder S; Noake C; Krol M; Oppe M; Kleijnen J; Severens H
    Health Technol Assess; 2013 Dec; 17(61):1-236. PubMed ID: 24351663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in PBM Business Practices in 2019: True Innovation or More of the Same?
    Motheral BR; Fairman KA
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1325-1333. PubMed ID: 32869706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care.
    Stamuli E; Bloor K; MacPherson H; Tilbrook H; Stuardi T; Brabyn S; Torgerson D
    BMC Gastroenterol; 2012 Oct; 12():149. PubMed ID: 23095351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of alternative pricing methods for drugs in California Workers' Compensation System: Fee-schedule pricing.
    Wilson L; Turkistani FA; Huang W; Tran DM; Lin TK
    PLoS One; 2018; 13(5):e0197449. PubMed ID: 29799850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic burden of irritable bowel syndrome in China.
    Zhang F; Xiang W; Li CY; Li SC
    World J Gastroenterol; 2016 Dec; 22(47):10450-10460. PubMed ID: 28058026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison.
    Sorenson C
    Issue Brief (Commonw Fund); 2010 Jul; 91():1-14. PubMed ID: 20614655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information.
    Mohseninejad L; Feenstra T; van der Horst HE; Woutersen-Koch H; Buskens E
    Eur J Health Econ; 2013 Dec; 14(6):947-57. PubMed ID: 23179163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options.
    Wechsler EV; Shah ED
    Drugs; 2021 Nov; 81(17):1953-1968. PubMed ID: 34727333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain.
    Mearin F; Caballero AM; Serra J; Brotons C; Tantiñà A; Fort E; Martínez-Cerezo FJ; Perelló A; Sánchez-Antolín G; Rey E; Angós Musgo R; Berdier R; Gómez-Rodríguez B; Clavé P; García-Alonso M; Torán-Monserrat P; Tack J
    Gastroenterol Hepatol; 2019 Mar; 42(3):141-149. PubMed ID: 30612850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System.
    Wilson L; Turkistani F; Tran DM; Huang W; Lin TK
    Appl Health Econ Health Policy; 2019 Apr; 17(2):231-242. PubMed ID: 30484140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.